Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer-Reference-Cited by-同舟云学术

Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer

Published:1992-02 Issue:2-3 Volume:28 Page:390-394
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gundersen S.,Høst H.,Lund E.,Hannisdal E.,Kvinnsland S.,Klepp O.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference9 articles.

1. Medroxyprogesterone acetate in combination with chemotherapy for advanced breast cancer: updated results and criticisms;Robustelli Della Cuna,1984

2. Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats;Formelli;Eur J Cancer Clin Oncol,1981

3. Revision of the standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC workshop;Eur J Cancer Clin Oncol,1980

4. Weekly adriamycin versus VAC in advanced breast cancer. A randomised trial;Gundersen;Eur J Cancer Clin Oncol,1986

5. Assessment of response to therapy in advanced breast cancer;Hayward;Cancer,1977

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53status predicts long-term survival in locally advanced breast cancer after primary chemotherapy;Acta Oncologica;2014-06-09

2. Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors;Anti-Cancer Drugs;2006-01

3. A Systematic Overview of Chemotherapy Effects in Breast Cancer;Acta Oncologica;2001-03-01

4. Adjuvant chemo-hormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up;The Breast;2001-02

5. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer;Cancer Treatment Reviews;2000-06